---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055647"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:35:36.102011+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago

## Summary
- NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)
- Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023
- Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M
- Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023
- Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D

## SEC filing metadata
- accession: 0000950170-24-055647
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/0000950170-24-055647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/acad-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055647
- JSON: https://secwatch.observer/filing/0000950170-24-055647.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055647.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported financial results for the three months ended March 31, 2024.
  - Period: the three months ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/0000950170-24-055647-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.